• Citer

Mature results of a randomized phase II multicenter study of exemestane versus tamoxifen as first-line hormone therapy for postmenopausal women with metastatic breast cancer.

par Paridaens, R. ;Dirix, Luc Y;Lohrisch, C;Beex, Louk;Nooij, Marianne;Cameron, David A;Biganzoli, Laura ;Cufer, T;Duchateau, L;Hamilton, Andrew;Lobelle, Jean Pierre;Piccart-Gebhart, Martine ;European Organization for the Research and Treatment of Cancer (EORTC)- Investigational Drug Branch for Breast Cancer (IDBBC),
Référence Annals of oncology, 14, 9, page (1391-1398)
Publication Publié, 2003-09

Article révisé par les pairs

• Détails
• Contenu

Titre:	Mature results of a randomized phase II multicenter study of exemestane versus tamoxifen as first-line hormone therapy for postmenopausal women with metastatic breast cancer.
Auteur:	Paridaens, R.; Dirix, Luc Y; Lohrisch, C; Beex, Louk; Nooij, Marianne; Cameron, David A; Biganzoli, Laura; Cufer, T; Duchateau, L; Hamilton, Andrew; Lobelle, Jean Pierre; Piccart-Gebhart, Martine; European Organization for the Research and Treatment of Cancer (EORTC)- Investigational Drug Branch for Breast Cancer (IDBBC),
Informations sur la publication:	Annals of oncology, 14, 9, page (1391-1398)
Statut de publication:	Publié, 2003-09
Sujet CREF:	Sciences bio-médicales et agricoles
MeSH keywords:	Adult
	Aged
	Aged, 80 and over
	Androstadienes -- adverse effects
	Androstadienes -- therapeutic use
	Antineoplastic Agents, Hormonal -- adverse effects
	Antineoplastic Agents, Hormonal -- therapeutic use
	Breast Neoplasms -- drug therapy
	Breast Neoplasms -- secondary
	Female
	Humans
	Middle Aged
	Postmenopause
	Tamoxifen -- adverse effects
	Tamoxifen -- therapeutic use
	Treatment Outcome
Note générale:	Clinical Trial
	Clinical Trial, Phase II
	Comparative Study
	Journal Article
	Multicenter Study
	Randomized Controlled Trial
	Research Support, Non-U.S. Gov't
Langue:	Anglais
Identificateurs:	urn:issn:0923-7534
	info:doi/10.1093/annonc/mdg362
	info:scp/0141836855
	info:pmid/12954578